Discordance in Immunohistochemical Status of Breast Cancer Post Neoadjuvant Chemotherapy.
作者信息
Agrawal Sanjit Kumar, Chatterjee Sanjoy, Arun Indu, Ahmed Rosina
机构信息
Department of Breast Oncosurgery, Tata Medical Center, Kolkata, India.
Department of Clinical Oncology, Tata Medical Center, Kolkata, India.
出版信息
Indian J Surg Oncol. 2017 Jun;8(2):245-246. doi: 10.1007/s13193-016-0606-1. Epub 2016 Dec 10.
Abstract
摘要
相似文献
1
Discordance in Immunohistochemical Status of Breast Cancer Post Neoadjuvant Chemotherapy.
Indian J Surg Oncol. 2017 Jun;8(2):245-246. doi: 10.1007/s13193-016-0606-1. Epub 2016 Dec 10.
2
Discordance of Estrogen & Progesterone Receptors After Neoadjuvant Chemotherapy in Breast Cancer- an Indian Study.
Indian J Surg Oncol. 2016 Sep;7(3):316-9. doi: 10.1007/s13193-016-0515-3. Epub 2016 Feb 25.
3
Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer.
Cancer Biomark. 2012;12(6):241-50. doi: 10.3233/CBM-130315.
4
Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy.
Future Oncol. 2022 Sep;18(30):3399-3408. doi: 10.2217/fon-2022-0198. Epub 2022 Sep 7.
5
Discordance of estrogen and progesterone receptors after neoadjuvant chemotherapy in locally advanced breast cancer.
J Cancer Res Ther. 2023 Apr;19(Supplement):S0. doi: 10.4103/jcrt.jcrt_873_21.
6
Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances.
Curr Oncol. 2022 Dec 8;29(12):9695-9710. doi: 10.3390/curroncol29120761.
7
Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer.
Clin Imaging. 2022 Sep;89:1-9. doi: 10.1016/j.clinimag.2022.05.002. Epub 2022 May 5.
8
Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer.
PLoS One. 2020 Apr 16;15(4):e0231895. doi: 10.1371/journal.pone.0231895. eCollection 2020.
9
Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.
J BUON. 2014 Oct-Dec;19(4):879-86.
10
The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer.
Tumori. 2011 Nov-Dec;97(6):704-10. doi: 10.1177/030089161109700605.
本文引用的文献
1
Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
Indian J Surg Oncol. 2016 Dec;7(4):397-406. doi: 10.1007/s13193-016-0523-3. Epub 2016 Apr 23.
2
Discordance of Estrogen & Progesterone Receptors After Neoadjuvant Chemotherapy in Breast Cancer- an Indian Study.
Indian J Surg Oncol. 2016 Sep;7(3):316-9. doi: 10.1007/s13193-016-0515-3. Epub 2016 Feb 25.
3
Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Breast Cancer (Dove Med Press). 2015 Dec 10;7:381-8. doi: 10.2147/BCTT.S94516. eCollection 2015.
4
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment.
Acta Pharmacol Sin. 2015 Oct;36(10):1219-27. doi: 10.1038/aps.2015.92. Epub 2015 Sep 21.
5
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts.
Cancer Res. 2015 Aug 1;75(15):2963-8. doi: 10.1158/0008-5472.CAN-15-0727. Epub 2015 Jul 15.
6
Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):914-21. eCollection 2015.
7
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21.
Zotero 插件